# Beam Therapeutics Inc.: financial statements, quarterly

BEAM · Nasdaq · CIK 1745999 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/beam.md) · [Financials](/companies/beam/financials.md) · [Filings](/companies/beam/filings.md) · [Insiders](/companies/beam/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/beam/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.2](/filings/0000950170-24-121104.md) | [316 d](/filings/0001193125-26-065194.md) | [7.4](/filings/0000950170-25-063966.md) | [11.8](/filings/0000950170-25-102393.md) | [14.3](/filings/0001193125-25-263542.md) | [30.1 d](/filings/0001193125-26-065194.md) | [7.5](/filings/0001193125-26-210338.md) | [8.5](/filings/0001193125-26-331541.md) | [9.7](/filings/0001193125-25-263542.md) | [114 d](/filings/0001193125-26-065194.md) | [31.7](/filings/0001193125-26-210338.md) | [0.5](/filings/0001193125-26-331541.md) |
| Research and development | $m | [100](/filings/0000950170-24-121104.md) | [140 d](/filings/0001193125-26-065194.md) | [84.8](/filings/0000950170-25-063966.md) | [87.0](/filings/0000950170-25-102393.md) | [94.3](/filings/0001193125-25-263542.md) | [101 d](/filings/0001193125-26-065194.md) | [98.8](/filings/0001193125-26-210338.md) | [102](/filings/0001193125-26-331541.md) | [110](/filings/0001193125-25-263542.md) | [99.3 d](/filings/0001193125-26-065194.md) | [105](/filings/0001193125-26-210338.md) | [95.1](/filings/0001193125-26-331541.md) |
| Operating income | $m | [(108)](/filings/0000950170-24-121104.md) | [133 d](/filings/0001193125-26-065194.md) | [(104)](/filings/0000950170-25-063966.md) | [(105)](/filings/0000950170-25-102393.md) | [(107)](/filings/0001193125-25-263542.md) | [(100) d](/filings/0001193125-26-065194.md) | [(119)](/filings/0001193125-26-210338.md) | [(120)](/filings/0001193125-26-331541.md) | [(127)](/filings/0001193125-25-263542.md) | [(17.4) d](/filings/0001193125-26-065194.md) | [(107)](/filings/0001193125-26-210338.md) | [(127)](/filings/0001193125-26-331541.md) |
| Income tax | $m | [0.0](/filings/0000950170-23-060683.md) | [1.4 d](/filings/0001193125-26-065194.md) | [0.0](/filings/0000950170-25-063966.md) | [0.0](/filings/0000950170-25-102393.md) | [0.0 d](/filings/0001193125-25-263542.md) | [0.0 d](/filings/0001193125-26-065194.md) | [0.0](/filings/0001193125-26-210338.md) | [0.0 d](/filings/0001193125-26-331541.md) | [0.0 d](/filings/0001193125-25-263542.md) | [0.0 d](/filings/0001193125-26-065194.md) | [0.0](/filings/0001193125-26-210338.md) | [0.0 d](/filings/0001193125-26-331541.md) |
| Net income | $m | [(96.1)](/filings/0000950170-24-121104.md) | [143 d](/filings/0001193125-26-065194.md) | [(98.7)](/filings/0001193125-25-263542.md) | [(91.1)](/filings/0001193125-25-263542.md) | [(96.7)](/filings/0001193125-25-263542.md) | [(90.4) d](/filings/0001193125-26-065194.md) | [(108)](/filings/0001193125-26-331541.md) | [(102)](/filings/0001193125-26-331541.md) | [(113)](/filings/0001193125-25-263542.md) | [244 d](/filings/0001193125-26-065194.md) | [(94.3)](/filings/0001193125-26-331541.md) | [(123)](/filings/0001193125-26-331541.md) |
| Diluted EPS | $ per share | [(1.22)](/filings/0000950170-24-121104.md) | not reported | [(1.21)](/filings/0000950170-25-063966.md) | [(1.11)](/filings/0000950170-25-102393.md) | [(1.17)](/filings/0001193125-25-263542.md) | not reported | [(1.23)](/filings/0001193125-26-210338.md) | [(1.00)](/filings/0001193125-26-331541.md) | [(1.10)](/filings/0001193125-25-263542.md) | not reported | [(0.91)](/filings/0001193125-26-210338.md) | [(1.18)](/filings/0001193125-26-331541.md) |
| Basic EPS | $ per share | [(1.22)](/filings/0000950170-24-121104.md) | not reported | [(1.21)](/filings/0000950170-25-063966.md) | [(1.11)](/filings/0000950170-25-102393.md) | [(1.17)](/filings/0001193125-25-263542.md) | not reported | [(1.23)](/filings/0001193125-26-210338.md) | [(1.00)](/filings/0001193125-26-331541.md) | [(1.10)](/filings/0001193125-25-263542.md) | not reported | [(0.91)](/filings/0001193125-26-210338.md) | [(1.18)](/filings/0001193125-26-331541.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [169](/filings/0000950170-24-121104.md) | [436](/filings/0001193125-26-065194.md) | [288](/filings/0000950170-25-063966.md) | [293](/filings/0000950170-25-102393.md) | [230](/filings/0001193125-25-263542.md) | [282](/filings/0001193125-26-065194.md) | [528](/filings/0001193125-26-210338.md) | [282](/filings/0001193125-26-331541.md) | [268](/filings/0001193125-25-263542.md) | [295](/filings/0001193125-26-331541.md) | [288](/filings/0001193125-26-210338.md) | [220](/filings/0001193125-26-331541.md) |
| Current assets | $m | [1,040](/filings/0000950170-23-060683.md) | [1,211](/filings/0000950170-25-026076.md) | [1,122](/filings/0000950170-24-053939.md) | [1,029](/filings/0000950170-24-091242.md) | [946](/filings/0000950170-24-121104.md) | [878](/filings/0001193125-26-065194.md) | [1,248](/filings/0000950170-25-063966.md) | [1,175](/filings/0000950170-25-102393.md) | [1,099](/filings/0001193125-25-263542.md) | [1,269](/filings/0001193125-26-331541.md) | [1,267](/filings/0001193125-26-210338.md) | [1,179](/filings/0001193125-26-331541.md) |
| Total assets | $m | [1,291](/filings/0000950170-23-060683.md) | [1,460](/filings/0000950170-25-026076.md) | [1,360](/filings/0000950170-24-053939.md) | [1,261](/filings/0000950170-24-091242.md) | [1,171](/filings/0000950170-24-121104.md) | [1,104](/filings/0001193125-26-065194.md) | [1,467](/filings/0000950170-25-063966.md) | [1,391](/filings/0000950170-25-102393.md) | [1,311](/filings/0001193125-25-263542.md) | [1,481](/filings/0001193125-26-331541.md) | [1,481](/filings/0001193125-26-210338.md) | [1,386](/filings/0001193125-26-331541.md) |
| Current liabilities | $m | [220](/filings/0000950170-23-060683.md) | [206](/filings/0000950170-25-026076.md) | [187](/filings/0000950170-24-053939.md) | [177](/filings/0000950170-24-091242.md) | [166](/filings/0000950170-24-121104.md) | [182](/filings/0001193125-26-065194.md) | [142](/filings/0000950170-25-063966.md) | [174](/filings/0000950170-25-102393.md) | [183](/filings/0001193125-25-263542.md) | [96.9](/filings/0001193125-26-331541.md) | [74.6](/filings/0001193125-26-210338.md) | [80.9](/filings/0001193125-26-331541.md) |
| Total liabilities | $m | [512](/filings/0000950170-23-060683.md) | [478](/filings/0000950170-25-026076.md) | [446](/filings/0000950170-24-053939.md) | [407](/filings/0000950170-24-091242.md) | [380](/filings/0000950170-24-121104.md) | [370](/filings/0001193125-26-065194.md) | [344](/filings/0000950170-25-063966.md) | [344](/filings/0000950170-25-102393.md) | [345](/filings/0001193125-25-263542.md) | [243](/filings/0001193125-26-331541.md) | [316](/filings/0001193125-26-210338.md) | [319](/filings/0001193125-26-331541.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [100](/filings/0001193125-26-210338.md) | [100](/filings/0001193125-26-331541.md) |
| Shareholders' equity | $m | [779](/filings/0000950170-24-121104.md) | [981](/filings/0001193125-26-065194.md) | [913](/filings/0001193125-25-263542.md) | [854](/filings/0001193125-25-263542.md) | [791](/filings/0001193125-25-263542.md) | [734](/filings/0001193125-26-331541.md) | [1,129](/filings/0001193125-26-331541.md) | [1,053](/filings/0001193125-26-331541.md) | [966](/filings/0001193125-25-263542.md) | [1,238](/filings/0001193125-26-331541.md) | [1,164](/filings/0001193125-26-331541.md) | [1,067](/filings/0001193125-26-331541.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(89.8) d](/filings/0000950170-24-121104.md) | [135 d](/filings/0001193125-26-065194.md) | [(99.7)](/filings/0000950170-25-063966.md) | [(83.0) d](/filings/0000950170-25-102393.md) | [(88.1) d](/filings/0001193125-25-263542.md) | [(76.4) d](/filings/0001193125-26-065194.md) | [(104)](/filings/0001193125-26-210338.md) | [(76.5) d](/filings/0001193125-26-331541.md) | [(81.5) d](/filings/0001193125-25-263542.md) | [(83.3) d](/filings/0001193125-26-065194.md) | [(129)](/filings/0001193125-26-210338.md) | [(66.1) d](/filings/0001193125-26-331541.md) |
| Capital expenditure | $m | [7.9 d](/filings/0000950170-24-121104.md) | [3.6 d](/filings/0001193125-26-065194.md) | [2.4](/filings/0000950170-25-063966.md) | [2.0 d](/filings/0000950170-25-102393.md) | [1.6 d](/filings/0001193125-25-263542.md) | [3.0 d](/filings/0001193125-26-065194.md) | [3.1](/filings/0001193125-26-210338.md) | [3.1 d](/filings/0001193125-26-331541.md) | [5.0 d](/filings/0001193125-25-263542.md) | [3.7 d](/filings/0001193125-26-065194.md) | [2.2](/filings/0001193125-26-210338.md) | [2.4 d](/filings/0001193125-26-331541.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [70.3](/filings/0000950170-23-060683.md) | [72.3](/filings/0000950170-24-053939.md) | [76.3](/filings/0000950170-24-091242.md) | [79.0](/filings/0000950170-24-121104.md) | [81.7](/filings/0000950170-25-063966.md) | [82.3](/filings/0000950170-25-102393.md) | [82.4](/filings/0001193125-25-263542.md) | [88.0](/filings/0001193125-26-210338.md) | [102](/filings/0001193125-26-331541.md) | [103](/filings/0001193125-25-263542.md) | [103](/filings/0001193125-26-210338.md) | [104](/filings/0001193125-26-331541.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 103,287,665 at 2026-07-28, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-331541.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.